Cargando…

Paradoxical worsening of bradycardia following atropine administration

INTRODUCTION: Bradyarrhythmias are a common entity in both emergency and out-of-hospital (OOH) medicine. In unstable bradycardic patients, paramedics will often initiate life-saving therapies in the OOH setting. Clinical guidelines for bradyarrhythmias are largely consistent across the globe, with i...

Descripción completa

Detalles Bibliográficos
Autores principales: Armour, Richard, Learning, Charmane, Trojanowski, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The College of Paramedics 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662156/
https://www.ncbi.nlm.nih.gov/pubmed/36451706
http://dx.doi.org/10.29045/14784726.2022.09.7.2.38
_version_ 1784830633330081792
author Armour, Richard
Learning, Charmane
Trojanowski, Jan
author_facet Armour, Richard
Learning, Charmane
Trojanowski, Jan
author_sort Armour, Richard
collection PubMed
description INTRODUCTION: Bradyarrhythmias are a common entity in both emergency and out-of-hospital (OOH) medicine. In unstable bradycardic patients, paramedics will often initiate life-saving therapies in the OOH setting. Clinical guidelines for bradyarrhythmias are largely consistent across the globe, with intravenous (IV) atropine recommended as a first-line therapy, escalating to IV adrenaline or isoprenaline and transcutaneous pacing where atropine is unsuccessful. In this case report, we describe a case in the OOH setting of ventricular standstill following the administration of atropine to a patient with bradycardia and 2:1 heart block. CASE PRESENTATION: The patient was a 77-year-old female presenting with a symptomatic 2:1 heart block. Following a single dose of 600 micrograms IV atropine, the patient deteriorated into ventricular standstill with a loss of consciousness and decorticate posturing. The patient was successfully managed with an IV infusion of adrenaline and subsequently received an implanted pacemaker in hospital. CONCLUSION: The paradoxical worsening of this patient’s bradycardia following atropine administration may have been related to the location of the heart block. It has been shown that patients with atrioventricular blocks at the level of the His-Purkinje fibres (infranodal) are at an increased risk of adverse events following atropine administration, while those at the nodal level or secondary to increased vagal tone are more likely to respond favourably. Paramedics should be prepared to manage unexpected adverse events secondary to atropine administration in patients with heart block.
format Online
Article
Text
id pubmed-9662156
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The College of Paramedics
record_format MEDLINE/PubMed
spelling pubmed-96621562023-09-01 Paradoxical worsening of bradycardia following atropine administration Armour, Richard Learning, Charmane Trojanowski, Jan Br Paramed J Case Report INTRODUCTION: Bradyarrhythmias are a common entity in both emergency and out-of-hospital (OOH) medicine. In unstable bradycardic patients, paramedics will often initiate life-saving therapies in the OOH setting. Clinical guidelines for bradyarrhythmias are largely consistent across the globe, with intravenous (IV) atropine recommended as a first-line therapy, escalating to IV adrenaline or isoprenaline and transcutaneous pacing where atropine is unsuccessful. In this case report, we describe a case in the OOH setting of ventricular standstill following the administration of atropine to a patient with bradycardia and 2:1 heart block. CASE PRESENTATION: The patient was a 77-year-old female presenting with a symptomatic 2:1 heart block. Following a single dose of 600 micrograms IV atropine, the patient deteriorated into ventricular standstill with a loss of consciousness and decorticate posturing. The patient was successfully managed with an IV infusion of adrenaline and subsequently received an implanted pacemaker in hospital. CONCLUSION: The paradoxical worsening of this patient’s bradycardia following atropine administration may have been related to the location of the heart block. It has been shown that patients with atrioventricular blocks at the level of the His-Purkinje fibres (infranodal) are at an increased risk of adverse events following atropine administration, while those at the nodal level or secondary to increased vagal tone are more likely to respond favourably. Paramedics should be prepared to manage unexpected adverse events secondary to atropine administration in patients with heart block. The College of Paramedics 2022-09-01 2022-09-01 /pmc/articles/PMC9662156/ /pubmed/36451706 http://dx.doi.org/10.29045/14784726.2022.09.7.2.38 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/2.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Armour, Richard
Learning, Charmane
Trojanowski, Jan
Paradoxical worsening of bradycardia following atropine administration
title Paradoxical worsening of bradycardia following atropine administration
title_full Paradoxical worsening of bradycardia following atropine administration
title_fullStr Paradoxical worsening of bradycardia following atropine administration
title_full_unstemmed Paradoxical worsening of bradycardia following atropine administration
title_short Paradoxical worsening of bradycardia following atropine administration
title_sort paradoxical worsening of bradycardia following atropine administration
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662156/
https://www.ncbi.nlm.nih.gov/pubmed/36451706
http://dx.doi.org/10.29045/14784726.2022.09.7.2.38
work_keys_str_mv AT armourrichard paradoxicalworseningofbradycardiafollowingatropineadministration
AT learningcharmane paradoxicalworseningofbradycardiafollowingatropineadministration
AT trojanowskijan paradoxicalworseningofbradycardiafollowingatropineadministration